Go Pro
→ A “bloodbath” Is Coming (From TradeSmith) (Ad)tc pixel
NASDAQ:OCUL

Ocular Therapeutix Q4 2025 Earnings Report

Ocular Therapeutix logo
$10.19 -0.53 (-4.94%)
Closing price 09/15/2026 04:00 PM Eastern
Extended Trading
$10.19 0.00 (-0.01%)
As of 05:53 AM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.
ProfileEarnings HistoryForecast

Ocular Therapeutix EPS Results

Actual EPS
-$0.29
Consensus EPS
-$0.33
Beat/Miss
Beat by +$0.04
One Year Ago EPS
-$0.29

Ocular Therapeutix Revenue Results

Actual Revenue
$13.25 million
Expected Revenue
$16.13 million
Beat/Miss
Missed by -$2.88 million
YoY Revenue Growth
-22.40%

Ocular Therapeutix Announcement Details

Quarter
Q4 2025
Date
2/5/2026
Time
Before Market Opens
Conference Call Date
Thursday, February 5, 2026
Conference Call Time
7:00AM ET

Upcoming Earnings

Ocular Therapeutix's Q3 2026 earnings is estimated for Tuesday, November 3, 2026, based on past reporting schedules, with a conference call scheduled at 8:00 AM ET. Check back for transcripts, audio, and key financial metrics as they become available.

Conference Call Resources

Powered by Quartr

Earnings Documents

Ocular Therapeutix's Q4 2025 Press ReleasePress Release
(8-K)

Ocular Therapeutix Earnings Headlines

Ocular Therapeutix, Inc. (NASDAQ:OCUL) Given Average Recommendation of "Moderate Buy" by Brokerages
 |  americanbankingnews.comhttps://www.americanbankingnews.com/?p=31026003
Ocular Therapeutix Plans to File Eye Disease Drug Marketing Application in Q4
September 15 at 5:54 PM  |  finance.yahoo.comhttps://finance.yahoo.com/healthcare/articles/ocular-therapeutix-plans-file-eye-113642279.html
A “bloodbath” Is Coming
Reports suggest some Silicon Valley billionaires are stockpiling gold, guns, and gas masks - or leaving the country entirely - as concerns grow about the next phase of the AI market. One AI insider says investors should reassess their positions before September 30, pointing to a critical shift ahead for tech and AI-related stocks.tc pixel
September 16 at 1:00 AM  |  TradeSmith (Ad)
Ocular Therapeutix Reports Positive Pre-NDA Meeting With FDA For AXPAXLI In Wet AMD
September 15 at 12:49 PM  |  rttnews.comhttps://www.rttnews.com/3691075/ocular-therapeutix-reports-positive-pre-nda-meeting-with-fda-for-axpaxli-in-wet-amd.aspx
Ocular Therapeutix™ Announces Positive Pre-NDA Meeting with U.S. FDA for AXPAXLI™ in Wet AMD
September 15 at 7:00 AM  |  globenewswire.comhttps://www.globenewswire.com/news-release/2026/09/15/3361910/0/en/ocular-therapeutix-announces-positive-pre-nda-meeting-with-u-s-fda-for-axpaxli-in-wet-amd.html
Ocular Therapeutix (OCUL): Faster Path To Approval Comes With Rising Costs
September 3, 2026  |  insidermonkey.comhttps://www.insidermonkey.com/blog/ocular-therapeutix-ocul-faster-path-to-approval-comes-with-rising-costs-1826879/
See More Ocular Therapeutix Headlines
Get Earnings Announcements in your inbox

Want to stay updated on the latest earnings announcements and upcoming reports for companies like Ocular Therapeutix? Sign up for Earnings360's daily newsletter to receive timely earnings updates on Ocular Therapeutix and other key companies, straight to your email.

About Ocular Therapeutix

Ocular Therapeutix (NASDAQ:OCUL) is a biopharmaceutical company focused on developing and commercializing therapies for diseases and conditions affecting the eye. The company uses its proprietary hydrogel-based technology to design sustained-release treatments intended to deliver medication to ocular tissues over extended periods and potentially reduce the need for frequent eye drops or injections.

Its commercial product, Dextenza, is a resorbable intracanalicular insert that delivers dexamethasone to the ocular surface for the treatment of inflammation and pain following ophthalmic surgery. Dextenza is inserted into the tear duct by an eye-care professional and is designed to provide medication for up to 30 days. The company’s development pipeline includes AXPAXLI, an extended-release intravitreal implant containing axitinib that is being studied for retinal diseases, including wet age-related macular degeneration.

Ocular Therapeutix was founded in 2006 and is headquartered in Bedford, Massachusetts. The company’s products and clinical programs are primarily directed at the U.S. ophthalmology market, while its research and development activities support potential international expansion. Ocular Therapeutix is led by President and Chief Executive Officer Pravin U. Dugel, an ophthalmologist and industry executive with experience in retinal disease and ophthalmic drug development.

View Ocular Therapeutix Profile
Earnings Tools